Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Nicotinamide (Vitamin B3; Niacinamide; Nicotinic acid amide), a water-soluble and active form of vitamin B3, is a potent and active component of coenzymes NAD and NADP. It is commonly used as a dietary supplement and medication. As a supplement, it is used by oral administration to prevent and treat pellagra. Nicotinamide also act as an inhibitor of sirtuins. Nicotinamide is also an inhibitor of poly(ADP-ribose) polymerase (PARP-1) enzymes. Poly(ADP-ribose) polymerase-1 (PARP-1) is found as a DNA repair enzyme. The excessive activation of PARP-1, such as ischemia and trauma, can deplete cellular nicotinamide adenine dinucleotide as a substrate and leads to brain cell death eventually.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
J Biol Chem.2002 Nov 22;277(47):45099-107.
|
Molecular Formula |
C6H6N2O
|
|
---|---|---|
Molecular Weight |
122.12
|
|
CAS # |
98-92-0
|
|
Related CAS # |
Nicotinamide;98-92-0
|
|
SMILES |
O=C(C1=C([H])N=C([H])C([H])=C1[H])N([H])[H]
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 8.1887 mL | 40.9433 mL | 81.8867 mL | |
5 mM | 1.6377 mL | 8.1887 mL | 16.3773 mL | |
10 mM | 0.8189 mL | 4.0943 mL | 8.1887 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04843553 | Completed | Drug: Oral Nicotinamide | Actinic Keratoses | Rhode Island Hospital | October 14, 2016 | Early Phase 1 |
NCT06007391 | Not yet recruiting | Drug: Nicotinamide | Nicotinamide Adverse Reaction | University Hospital, Angers | September 2023 | Phase 2 Phase 3 |
NCT03789175 | Completed Has Results | Dietary Supplement: Nicotinamide Riboside (NR) |
Cancer Skin Fibroblasts |
National Heart, Lung, and Blood Institute (NHLBI) |
March 25, 2019 | Phase 1 Phase 2 |
NCT03432871 | Completed | Dietary Supplement: Nicotinamide Riboside |
Mitochondrial Diseases Mitochondrial Myopathies |
Cambridge University Hospitals NHS Foundation Trust |
December 8, 2017 | Not Applicable |
The NAD+ salvage pathway.Nicotinamide generated by Sir2 is converted into nicotinic acid by Pnc1 and subsequently back into NAD+ in three steps.YNR073C and YEL070W are putative NAD+glycohydrolases. Question marks represent enzymes present in bacteria without obvious homologs in yeast. Abbreviations:NAD +, nicotinamide adenine dinucleotide;NaMN, nicotinic acid mononucleotide; NaAD, desamido-NAD+; NADP +, nicotinamide adenine dinucleotide phosphate. td> |
Localization of Sir2-GFP in the presence of nicotinamide (NAM). A, wild-type strains containing SIR2-GFP (YDS1078), SIR3-GFP(YDS1099), or GFP-SIR4 (YDS1097), and an isogenicsir2 derivative expressing SIR3-GFP (YDS1109), were grown for the indicated times in the presence of 5 mmnicotinamide. GFP fluorescence was detected in live cells.B, the SIR2-GFP strain was deleted forHML(YDS1784) arrested in G1 by 10 μg/ml α-factor and treated with 0 or 5 mm nicotinamide. Times indicated are post-nicotinamide treatment. td> |
Model for noncompetitive inhibition of Sirs by nicotinamide. A, the Sir2 family of deacetylases contains an NAD+ binding pocket divided into three distinct regions. The adenine-ribose moiety of NAD+binds the A site whereas, in the absence of acetylated substrate, the nicotinamide moiety is bound to the B site. B, in the presence of an acetyllysine (K) a rotation around a phosphodiester bond of the pyrophosphate moiety would position the nicotinamide group near the C site where hydrolysis and subsequent nicotinamide release may take place. C, when present at elevated levels, free nicotinamide may bind to the C site preventing the conformational change and hydrolysis of NAD+. td> |